Idorsia Reports 74% QUVIVIQ Sales Growth in Q1 2026, Expands European Market Reach

Key Takeaways

• QUVIVIQ (daridorexant) sales surged 74% year-over-year in Q1 2026, demonstrating strong market adoption for Idorsia’s insomnia treatment
• Strong pediatric daridorexant data is being prepared for publication, potentially expanding treatment options for younger patients with sleep disorders
• European market expansion accelerating with co-promotion partnerships planned across Benelux, Ireland, Norway, Denmark, and Central/Eastern Europe

---

Idorsia Delivers Strong Q1 Performance

Swiss biopharmaceutical company Idorsia Ltd. announced robust first-quarter 2026 financial results, highlighted by a remarkable 74% year-over-year sales increase for its insomnia medication QUVIVIQ (daridorexant). The company’s ad hoc announcement pursuant to Art. 53 LR signals continued momentum in the competitive sleep disorder treatment market.

QUVIVIQ Market Expansion Strategy

Idorsia is aggressively expanding QUVIVIQ’s European footprint through strategic co-promotion partnerships. The company plans market introductions across multiple regions, including Benelux countries, Ireland, Norway, Denmark, and Central and Eastern European markets. This expansion strategy aims to capitalize on the growing demand for innovative insomnia treatments and maximize the drug’s commercial potential.

Pediatric Data Opens New Opportunities

The company is preparing to publish “strong pediatric daridorexant data” and engage with regulatory authorities regarding next steps for younger patient populations. This development could significantly expand QUVIVIQ’s addressable market, as pediatric sleep disorders represent an underserved therapeutic area with limited treatment options.

Pipeline Progress and Partnerships

Beyond QUVIVIQ, Idorsia continues advancing its broader pipeline with ongoing partnering discussions for TRYVIO™/JERAYGO™ involving multiple parties. These partnership negotiations could provide additional revenue streams and validation for the company’s drug development capabilities.

Market Impact and Future Outlook

The 74% sales growth demonstrates QUVIVIQ’s strong market acceptance among healthcare providers and patients seeking effective insomnia treatments. As sleep disorders affect millions globally, Idorsia’s expansion strategy positions the company to capture significant market share in the growing sleep medicine sector. The combination of geographic expansion, potential pediatric indications, and pipeline advancement creates multiple growth catalysts for sustained performance.

---

Frequently Asked Questions

What is QUVIVIQ and how does it treat insomnia?

QUVIVIQ (daridorexant) is Idorsia’s orexin receptor antagonist approved for treating insomnia in adults. It works by blocking orexin receptors in the brain that regulate wakefulness, helping patients fall asleep and stay asleep.

When will QUVIVIQ be available in new European markets?

Idorsia is planning market introductions in Benelux, Ireland, Norway, Denmark, and Central/Eastern Europe, though specific launch dates have not been disclosed. The company is establishing co-promotion partnerships to accelerate these rollouts.

Could QUVIVIQ be approved for children with sleep disorders?

Idorsia is preparing to publish pediatric daridorexant data and engage with regulatory authorities about next steps. While promising, any pediatric approval would require regulatory review and approval, with timelines dependent on the data strength and regulatory processes.